On October 6, 2017, Integra LifeSciences Holdings Corporation (“Integra”) completed its previously announced divestiture of certain assets to the asset purchase agreement (the “Divestiture Agreement”), dated September 8, 2017, by and among Natus Medical Incorporated (“Natus”), Integra and certain of Integra’s subsidiaries. The assets sold to Natus to the Divestiture Agreement are related to Integra’s intercranial pressure monitoring and U.S. fixed pressure valve shunt systems businesses along with certain assets related to the Codman U.S. dural graft implant, external ventricular drainage catheter and cerebrospinal fluid collection systems businesses that Integra purchased from DePuy Synthes, Inc., a wholly-owned subsidiary of Johnson& Johnson, on October 2, 2017. Under the terms of the Divestiture Agreement, Natus paid an aggregate purchase price of $46,386,745, subject to customary purchase price adjustments.

The foregoing description of the Divestiture Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Divestiture Agreement, which will be an exhibit to Integra’s Quarterly Report on Form 10-Q for the quarter ended September30, 2017. All summaries and descriptions of the Divestiture Agreement set forth above are qualified in their entirety by the actual documents.

About INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART)

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.